All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell.

Kirk Milhoan, MD, PhD, has been fired from his role as a pediatric cardiologist. His wife and others say he was let go because he is now the chair of the CDC’s Advisory Committee on Immunization Practices.

It is still unclear which imaging exams President Donald Trump underwent to evaluate his cardiovascular health. The White House shared a memo Monday as an attempt to put this topic to bed—but questions remain. 

A variety of CPT code changes take effect in 2026, and many of them will make a direct impact on interventional cardiology. Arnold Seto, MD, spoke to Cardiovascular Business about these updates for a new video interview.

On Dec. 11, the Alaskan cardiologist was captured as part of a months-long investigation and charged with 10 counts of possessing child sexual abuse materials. The fire at his home occurred two days later.

Interventional cardiology's second Match Day was a significant success. Due to a lack of candidates, however, dozens of fellowship positions remain unfilled. 

For years, imaging experts have predicted that CCTA may become the primary imaging modality for coronary artery disease and eliminate the need for invasive diagnostic catheterizations. That prediction is now coming true.

Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.” 

ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike.

Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions.